GTS Securities’s Ironwood Pharmaceuticals IRWD Stock Holding History

GTS Securities’s Portfolio IRWD Stock Details IRWD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-10,412	Closed	-$100K	–	4211
2023 Q3	$100K	Buy	+10,412	New	+$102K	﹤0.01%	3601

Other funds holding IRWD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

GTS Securities's IRWD Position: Q4 2023 in Review

GTS Securities sold out of Ironwood Pharmaceuticals (IRWD) in Q4 2023, closing a stake of 10,412 shares — an estimated $100K sold.

GTS Securities first reported a position in IRWD in Q3 2023 and held it in 1 quarter. The position peaked at $100K in Q3 2023. 251 funds tracked by Wall St. Rank hold IRWD as of Q4 2023.

GTS Securities reported no remaining Ironwood Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
GTS Securities sold 10,412 Ironwood Pharmaceuticals shares in Q4 2023, an estimated $100K.
GTS Securities first reported a position in Ironwood Pharmaceuticals in Q3 2023 and held it in 1 quarter.
GTS Securities's Ironwood Pharmaceuticals position peaked at $100K in Q3 2023.
251 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q4 2023.

Based on GTS Securities's 13F filing for Q4 2023, filed 15 Feb 2024.